drugset / Trial / NCT06216054

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects

NCT06216054 ↗

Phase 1 Completed 40 enrolled Luye Pharma Group Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

This is a single-center, randomized, double-blind, placebo-controlled, multiple-ascending doses trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy subjects under fasting state, providing the rationale information for later clinical trials.

Timeline

Start
2023-12-19
Primary completion
2024-07-29
Completion
2024-07-29

Drugs

EvaluationDrugModalityDoseRoute
Subject LPM3770164 Unknown 5 mg Oral
Subject LPM3770164 Unknown 30 mg Oral